

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number  
**WO 02/24649 A1**

- (51) International Patent Classification<sup>7</sup>: **C07D 211/58**, A61K 31/435, A61P 33/06 (74) Agent: **HOFMANN, Dieter**; StratAll, Therwilerstrasse 87, CH-4153 Reinach (CH).
- (21) International Application Number: PCT/EP01/10272 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 6 September 2001 (06.09.2001) (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: PCT/EP00/09328 25 September 2000 (25.09.2000) EP
- (71) Applicant (*for all designated States except US*): **ACTELION PHARMACEUTICALS LTD** [CH/CH]; Actelion LTD, Gewerbestrasse 16, CH-4123 Allschwil (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BOSS, Christoph** [CH/CH]; Muesmattweg 98, CH-4123 Allschwil (CH). **FISCHLI, Walter** [CH/CH]; Obertorweg 64, CH-4123 Allschwil (CH). **MEYER, Solange** [FR/FR]; 10A, rue du ruisseau, F-68440 Schlierbach (FR). **RICHARD-BILDSTEIN, Sylvia** [FR/FR]; 34A, rue d'Ottmarsheim, F-68170 Rixheim (FR). **WELLER, Thomas** [CH/CH]; Hoelzlistrasse 58, CH-4102 Binningen (CH).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA

(57) Abstract: The invention relates to novel compounds which are substituted amino-aza-cycloalkane derivatives of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of the plasmodium falciparum protease plasmepsin II or related aspartic proteases.



WO 02/24649 A1

## SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA

5

The invention relates to novel compounds which are substituted amino-aza-cycloalkane derivatives of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general  
10 formula I and especially their use as inhibitors of the plasmodium falciparum protease plasmepsin II or related aspartic proteases.

### ***Background of the invention:***

Malaria is one of the most serious and complex health problems affecting  
15 humanity in the 21<sup>st</sup> century. The disease affects about 300 million people worldwide, killing 1 to 1.5 million people every year. Malaria is an infectious disease caused by four species of the protozoan parasite Plasmodium, P. falciparum being the most severe of the four. All attempts to develop vaccines against P. falciparum have failed so far. Therefore, therapies and preventive  
20 measures against malaria are confined to drugs. However, resistance to many of the currently available antimalarial drugs is spreading rapidly and new drugs are needed.

P. Falciparum enters the human body by way of bites of the female anophelino mosquito. The plasmodium parasite initially populates the liver,  
25 and during later stages of the infectious cycle reproduces in red blood cells. During this stage, the parasite degrades hemoglobin and uses the degradation products as nutrients for growth [1]. Hemoglobin degradation is mediated by serine proteases and aspartic proteases. Aspartic proteases have been shown to be indispensable to parasite growth. A non-selective  
30 inhibitor of aspartic proteases, Pepstatin, inhibits the growth of P. falciparum in red blood cells in vitro. The same results have been obtained with analogs of pepstatin [2], [3]. These results show that inhibition of parasite aspartic proteases interferes with the life cycle of P. falciparum. Consequently, aspartic proteases are targets for antimalarial drug development.

The present invention relates to the identification of novel low molecular weight, non-peptidic inhibitors of the plasmodium falciparum protease plasmepsin II or other related aspartic proteases to treat and/or prevent malaria.

- 5 The compounds of general formula I were tested against plasmepsin II, HIV-protease, human cathepsin D, human cathepsin E and human renin in order to determine their biological activity and their selectivity profile.

### **In vitro Assays:**

10

**The fluorescence resonance energy transfer (FRET) assay for HIV, plasmepsin II, human cathepsin D and human cathepsin E.**

The assay conditions were selected according to reports in the literature [4 - 7].

- 15 The FRET assay was performed in white polysorp plates (Fluoronunc, cat n° 437842 A). The assay buffer consisted of 50 mM Na acetate pH 5, 12,5% glycerol, 0.1% BSA + 392 mM NaCl (for HIV-protease).

The incubates per well were composed of:

- 160 µl buffer
- 20 - 10 µl inhibitor (in DMSO)
- 10 µl of the corresponding substrate in DMSO (see table A) to a final concentration of 1 µM
- 20 µl of enzyme to a final amount of x ng per assay tube (x = 10 ng/assay tube plasmepsin II, x = 100 ng/assay tube HIV-protease, x = 10
- 25 ng/assay tube human cathepsin E and x = 20 ng/assay tube human cathepsin D)

- The reactions were initiated by addition of the enzyme. The assay was incubated at 37°C for 30 min (for human cathepsin E), 40 min (for plasmepsin II and HIV-protease) or 120 min (for human cathepsin D). The reactions were stopped by
- 30 adding 10% (v/v) of a 1 M solution of Tris-base. Product-accumulation was monitored by measuring the fluorescence at 460 nm.

Auto-fluorescence of all the test substances is determined in assay buffer in the absence of substrate and enzyme and this value was subtracted from the final signal.

5

Aspartyl protease	substrate		enzyme concentration ng/at (nM)	Buffer	pH	incubation time minutes
	sequence	substrate concentration $\mu$ M				
HIV	Dabcyl-Abu-SQNY:PIVN-EDANS	1	100 (22.5)	50 mM Na acetate ; 12,5 % glycerol ; 0.1 % BSA 392 mM NaCl	5	40
Plasmeprin II	Dabcyl-ERNIeF:LSFP-EDANS	1	10 (1.25)	50 mM Na acetate ; 12,5 % glycerol ; 0.1% BSA	5	40
h Cathepsin D	Dabcyl-ERNIeF:LSFP-EDANS	1	20 (2.5)	50 mM Na acetate ; 12,5 % glycerol ; 0.1% BSA	5	120
h Cathepsin E	Dabcyl-ERNIeF:LSFP-EDANS	1	10 (1.25)	50 mM Na acetate ; 12,5 % glycerol ; 0.1% BSA	5	30

Table A: Summary of the conditions used for the aspartyl proteases fluorescent assays. (at = assay tube)

10

### Enzymatic in vitro assay for renin:

The enzymatic in vitro assay was performed in polypropylene plates (Nunc, Cat No 4-42587A). The assay buffer consisted of 100 mM sodium phosphate, pH 7.4, including 0.1% BSA. The incubates were composed of 190  $\mu$ L per well of an enzyme mix and 10  $\mu$ L of renin inhibitors in DMSO. The enzyme mix was premixed at 4°C and composed as follows:

- human recombinant renin (0.16 ng/mL)
- synthetic human tetradecapeptide renin substrate (0.5  $\mu$ M)
- hydroxyquinoline sulfate (0.1 mM)

20

The mixtures were then incubated at 37°C for 3 h.

To determine the enzymatic activity and its inhibition, the accumulated Angiotensin I was detected by an enzyme immunoassay (EIA). 10  $\mu$ L of the incubates or standards were transferred to immuno plates which were previously coated with a covalent complex of Angiotensin I and bovine serum albumin (Ang

25

I – BSA). 190 µL of Angiotensin I-antibodies were added and a primary incubation made at 4°C over night. The plates were washed 3 times and then incubated for one hour at room temperature with a *biotinylated anti-rabbit antibody*. Thereafter, the plates were washed and incubated at room  
5 temperature for 30 min with a *streptavidin-peroxidase complex*. After washing the plates, the *peroxidase substrate* ABTS (2,2'-Azino-di-(3-ethyl-benzthiazolinsulfonate), was added and the plates incubated for 10-30 min at room temperature. After stopping the reaction with 0.1 M citric acid pH 4.3 the plate is evaluated in a microplate reader at 405 nm.

**Table 1:** IC<sub>50</sub> values (nM) for selected compounds on plasmepsin II:

<b>Example Nr:</b>	<b>IC<sub>50</sub> (nM) on plasmepsin II</b>
Example 1	70
Example 2	1500
Example 3	1700
Example 6	1800
Example 7	462
Example 9	1700
Example 10	1200
Example 11	3200
Example 13	2400
Example 14	84
Example 15	1300
Example 16	1300
Example 18	148
Example 22	793
Example 24	427
Example 25	220
Example 26	497
Example 30	695
Example 31	210
Example 32	18
Example 33	96
Example 34	1970
Example 35	1700
Example 36	164
Example 37	1530


**References:**

1. Goldberg, D. E., Slater, A. F., Beavis, R., Chait, B., Cerami, A.,  
5 Henderson, G. B., Hemoglobin degradation in the human malaria  
pathogen *Plasmodium falciparum*: a catabolic pathway initiated by a  
specific aspartic protease; *J. Exp. Med.*, 1991, **173**, 961 – 969.
2. Francis, S. E., Gluzman, I. Y., Oksman, A., Knickerbocker, A., Mueller,  
R., Bryant, M. L., Sherman, D. R., Russell, D. G., Goldberg, D. E.,  
10 Molecular characterization and inhibition of a *Plasmodium falciparum*  
aspartic hemoglobinase; *Embo. J.*, 1994, **13**, 306 – 317.
3. Moon, R. P., Tyas, L., Certa, U., Rupp, K., Bur, D., Jaquet, H., Matile, H.,  
Loetscher, H., Grueninger-Leitch, F., Kay, J., Dunn, B. M., Berry, C.,  
Ridley, R. G., Expression and characterization of plasmepsin I from  
15 *Plasmodium falciparum*, *Eur. J. Biochem.*, 1997, **244**, 552 – 560.
4. Carroll, C. D., Johnson, T. O., Tao, S., Lauri, G., Orlowski, M., Gluzman,  
I.Y., Goldberg, D. E., Dolle, R. E., (1998). "Evaluation of a structure-  
based statine cyclic diamino amide encoded combinatorial library against  
plasmepsin II and cathepsin D". *Bioorg Med Chem Lett* ; 8(22), 3203 –  
20 3206.
5. Peranteau, A. G., Kuzmic, P., Angell, Y., Garcia-Echeverria, C., Rich, D.  
H., (1995). "Increase in fluorescence upon the hydrolysis of tyrosine  
peptides: application to proteinase assays". *Anal Biochem*; 227(1):242 –  
245.
- 25 6. Gulnik, S. V., Suvorov, L. I., Majer, P., Collins, J., Kane, B. P., Johnson,  
D. G., Erickson, J. W., (1997). "Design of sensitive fluorogenic substrates  
for human cathepsin D". *FEBS Lett*; 413(2), 379 – 384.
7. Robinson, P. S., Lees, W. E., Kay, J., Cook, N. D., (1992). "Kinetic  
parameters for the generation of endothelins-1, -2 and -3 by human  
30 cathepsin E". *Biochem J*; 284 (Pt 2): 407 – 409.
8. J. March, *Advanced Organic Chemistry*, pp 918-919, and refs. cited  
therein; 4<sup>th</sup>Ed., John Wiley & Sons, **1992**.

9. A. Kubo, N. Saito, N. Kawakami, Y. Matsuyama, T. Miwa, *Synthesis*, **1987**, 824-827.
10. R. K. Castellano, D. M. Rudkevich, J. Rebek, Jr., *J. Am. Chem. Soc.*, **1996**, *118*, 10002-10003.
- 5 11. U. Schöllkopf, *Pure Appl. Chem.*, 1983, *55*, 1799-1806 and refs. cited therein; U. Schöllkopf, *Top. Curr. Chem.*, 1983, *109*, 65-84 and refs. cited therein; T. Wirth, *Angew. Chem. Int. Ed. Engl.*, 1997, *36*, 225-227 and refs. cited therein.
12. T. W. Greene, P. G. M. Wutts, *Protective groups in organic synthesis*; 10 *Wiley-Interscience*, **1991**.
13. P. J. Kocienski, *Protecting Groups*, Thieme, **1994**.
14. J. A. Radding, Development of Anti-Malarial Inhibitors of Hemoglobinas, *Annual Reports in Medicinal Chemistry*, **34**, 1999, 159 – 168.
- 15 15. D. F. Wirth, Malaria: A Third World Disease in Need of First World Drug Development, *Annual Reports in Medicinal Chemistry*, **34**, 1999, 349 - 358.



The present invention relates to novel, low molecular weight organic compounds, which are substituted amino-aza-cycloalkanes of the **general formula I**:



**General Formula I**

wherein

**Q** represents  $-\text{SO}_2-\text{R}^1$ ;  $-\text{CO}-\text{R}^1$ ;  $-\text{CO}-\text{NH}-\text{R}^1$ ;  $-\text{CO}-\text{N}(\text{R}^1)(\text{R}^2)$ ;  $-\text{CO}-\text{OR}^1$ ;  
 $-(\text{CH}_2)_p-\text{R}^1$ ;  $-(\text{CH}_2)_p-\text{CH}(\text{R}^1)(\text{R}^2)$ ;

**X** represents  $-\text{SO}_2-\text{R}^1$ ;  $-\text{CO}-\text{R}^1$ ;  $-\text{CO}-\text{NH}-\text{R}^1$ ;  $-\text{CO}-\text{N}(\text{R}^1)(\text{R}^2)$ ;  $-\text{CO}-\text{OR}^1$ ;  
 $-(\text{CH}_2)_p-\text{R}^1$ ;  $-(\text{CH}_2)_p-\text{CH}(\text{R}^1)(\text{R}^2)$ ; hydrogen;

**R<sup>1</sup>**, **R<sup>2</sup>** and **R<sup>3</sup>** represent lower alkyl; lower alkenyl; aryl; heteroaryl; cycloalkyl;  
heterocyclyl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-lower alkyl;  
heterocyclyl-lower alkyl; aryl-lower alkenyl; heteroaryl-lower alkenyl; cycloalkyl-  
lower alkenyl; heterocyclyl-lower alkenyl;

**R<sup>4</sup>** represents hydrogen;  $-\text{CH}_2-\text{OR}^5$ ;  $-\text{CO}-\text{OR}^5$ ;

$R^5$  represents hydrogen, lower alkyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl-lower alkyl; aryl-lower alkyl; heteroaryl-lower alkyl; heterocyclyl-lower alkyl;

5  $t$  represents the whole numbers 0 (zero) or 1 and in case  $t$  represents the whole number 0 (zero),  $R^4$  is absent;

$m$  represents the whole numbers 2, 3 or 4;

10  $n$  represents the whole numbers 1 or 2;

$p$  represents the whole numbers 0 (zero), 1 or 2;

and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of  
15 diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof

In the definitions of the **general formula I** – if not otherwise stated – the expression lower means straight and branched chain groups with one to  
20 seven carbon atoms, preferably 1 to 4 carbon atoms which may optionally be substituted with hydroxy or lower alkoxy. Examples of lower alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl, tert.-butyl, pentyl, hexyl, heptyl. Examples of lower alkoxy groups are methoxy, ethoxy, propoxy, iso-butoxy, sec.-butoxy and tert.-butoxy etc. Lower alkylendioxy-groups as  
25 substituents of aromatic rings onto two adjacent carbon atoms are preferably methylen-dioxy and ethylen-dioxy. Lower alkylen-oxy groups as substituents of aromatic rings onto two adjacent carbon atoms are preferably ethylen-oxy and propylen-oxy. Examples of lower alkanoyl-groups are acetyl, propanoyl and butanoyl. Lower alkenylen means e.g. vinylen, propenylen and butenylen.

30

The expression **cycloalkyl**, alone or in combination, means a saturated cyclic hydrocarbon ring system with 3 to 6 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be substituted with lower alkyl groups.

The expression **heterocyclyl**, alone or in combination, means saturated or unsaturated (but not aromatic) five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which rings may be substituted with lower alkyl, lower alkenyl, aryl, aryl-  
5 lower alkyloxy, aryl-oxy, amino, bis-(lower alkyl)-amino, alkanoyl-amino, halogen, nitro, hydroxy, lower alkoxy, phenoxy; examples of such rings are morpholinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, 1,4-dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dihydropyrrolyl, imidazolidinyl, dihydropyrazolyl, pyrazolidinyl  
10 etc. and substituted derivatives of such type rings with substituents as outlined hereinbefore.

The expression **heteroaryl**, alone or in combination, means six-membered aromatic rings containing one to four nitrogen atoms; benzofused six-membered  
15 aromatic rings containing one to three nitrogen atoms; five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; benzo-fused five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; five membered aromatic rings containig one oxygen and one nitrogen atom and benzo fused derivatives thereof; five membred aromatic rings containing a sulfur  
20 and nitrogen or oxygen atom and benzo fused derivatives thereof; five membered aromatic rings containing three nitrogen atoms and benzo fused derivatives thereof or the tetrazolyl ring; examples of such rings are furanyl, thienyl, pyrrolyl, pyridinyl, indolyl, quinolinyl, isoquinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, imidazolyl, triazinyl, thiazinyl,  
25 pyridazinyl, oxazolyl, etc. whereby such ring systems may be mono-, di- or tri-substituted with aryl; aryloxy, aryl-lower alkyl-oxy, lower alkyl; lower alkenyl; lower alkyl-carbonyl; amino; lower alkyl-amino; bis-(lower-alkyl)-amino; lower alkanoyl-amino;  $\omega$ -amino-lower alkyl; halogen; hydroxy; carboxyl; lower alkoxy; vinyloxy; allyloxy;  $\omega$ -hydroxy-lower alkyl; nitro; cyano; amidino; trifluoromethyl;  
30 lower alkyl-sulfonyl etc.

The expression **aryl**, alone or in combination, means six membered aromatic rings and condensed systems like naphthyl or indenyl etc. whereby such ring

systems may be mono-, di- or tri-substituted with aryl, aryloxy, aryl-lower alkyloxy, lower alkyl, lower alkenylen, lower alkyl-carbonyl, aryl-carbonyl, amino, lower alkyl-amino, aryl-amino, bis-(lower-alkyl)-amino, lower alkanoyl-amino,  $\omega$ -amino-lower alkyl, halogen, hydroxy, carboxyl, lower alkoxy, vinyloxy, allyloxy,  $\omega$ -hydroxy-lower alkyl,  $\omega$ -hydroxy-lower alkoxy, nitro, cyano, amidino, trifluoromethyl, lower alkyl-sulfonyl etc.

It is understood that the substituents outlined relative to the expressions cycloalkyl, heterocyclyl, heteroaryl and aryl have been omitted in the definitions of the general formulae I to V and in claims 1 to 5 for clarity reasons but the definitions in formulae I to V and in claims 1 to 5 should be read as if they are included therein.

The expression pharmaceutically acceptable salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid; sulfuric acid, phosphoric acid, nitric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, methysulfonic acid, p- toluolsulfonic acid and the like or in case the compound of formula I is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide etc.

The compounds of the general formula I can contain one or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers, diastereomers, mixtures of diastereomers, diastereomeric racemates and mixtures of diastereomeric racemates.

The present invention encompasses all these forms. Mixtures may be separated in a manner known per se, i.e. by column chromatography, thin layer chromatography, HPLC, crystallization etc.

The compounds of the general formula I and their pharmaceutically acceptable salts may be used as therapeutics e.g. in form of pharmaceutical compositions. They may especially be used to in prevention or treatment of malaria. These compositions may be administered in enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form

like sprays or rectally in form of suppositories. These compounds may also be administered in intramuscular, parenteral or intravenous form, e.g. in form of injectable solutions.

- 5 These pharmaceutical compositions may contain the compounds of formula I as well as their pharmaceutically acceptable salts in combination with inorganic and/or organic excipients which are usual in the pharmaceutical industry like lactose, maize or derivatives thereof, talcum, stearinic acid or salts of these materials.

10

For gelatine capsules vegetable oils, waxes, fats, liquid or half-liquid polyols etc. may be used. For the preparation of solutions and sirups e.g. water, polyols saccharose, glucose etc. are used. Injectables are prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin, liposomes etc. Suppositories  
15 are prepared by using natural or hydrogenated oils, waxes, fatty acids (fats), liquid or half-liquid polyols etc.

20

The compositions may contain in addition preservatives, stability improving substances, viscosity improving or regulating substances, solubility improving  
substances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer, anti-oxidants etc.

25


The compounds of formula I may also be used in combination with one or more other therapeutically useful substances e. g. with other antimalarials like quinolines (quinine, chloroquine, amodiaquine, mefloquine, primaquine, tafenoquine etc), peroxide antimalarials (artemisinin derivatives), pyrimethamine-sulfadoxine antimalarials (e.g. Fansidar etc), hydroxynaphtoquinones (e.g. atovaquone etc.), acroline-type antimalarials (e. g. pyronaridine etc) etc.

30

The dosage may vary within wide limits but should be adapted to the specific situation. In general the dosage given in oral form should daily be between about 3 mg and about 3 g, preferably between about 10 mg and about 1 g, especially preferred between 5 mg and 300 mg, per adult with a body weight of about 70

kg. The dosage should be administered preferably in 1 to 3 doses per day which are of equal weight. As usual, children should receive lower doses which are adapted to body weight and age.

Preferred compounds are compounds of the **formula II**



**Formula II**


wherein

- 5 **X, Q, t, R<sup>3</sup> and R<sup>4</sup>** are as defined in general formula I above

and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof.

10

Also preferred compounds are compounds of **formula III**




**Formula III**

wherein

**Q**, **t**, **R**<sup>3</sup> and **R**<sup>4</sup> are as defined in general formula I above

and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of  
5 diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates  
and pharmaceutically acceptable salts thereof.

Especially preferred are also compounds of the **formula IV**



**Formula IV**

10


wherein

**Q** is as defined in general formula I above

15 and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of  
diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates  
and pharmaceutically acceptable salts thereof.




Especially preferred are compounds of the **formula V**



- 5 and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof.
- 10 The compounds of the **general formula I** of the present invention may be prepared according to the general sequences of reactions outlined below, wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $Q$ ,  $X$ ,  $t$ ,  $m$ ,  $n$  and  $p$  are as defined in general formula I above (for simplicity and clarity reasons, only parts of the synthetic possibilities which lead to compounds of formulae I to V are described). For general methods
- 15 of certain steps see also pages 19 – 23.

Scheme 1: Preparation of substituted 4-amino-N-benzyl-piperidines:



5 Typical procedure for the reductive amination (Synthesis of compounds 2):

The amine (1) and the aldehyde  $\{\text{R}^3\text{-CHO}\}$  (1.5 eq.) are mixed in anhydrous methanol and stirred for 6 h. The mixture is then treated with sodium borohydride (1.5 eq.) and stirred for 2 h. Purified Amberlyst 15 or another suitable scavenger  
 10 is added and the suspension is shaken for 12 h. The resin is then separated by filtration and washed with methanol. The secondary amine 2 is removed from the resin by adding a 2 M methanolic ammonia solution. The resin is drained after 30 min and washed with methanol. The filtrate is evaporated to yield the pure secondary amine 2.

Typical procedure for the acylation (Synthesis of compounds **3**):

To a solution of the amine **2** in anhydrous ethyl acetate is added vacuum dried Amberlyst 21 or another suitable scavenger followed by the addition of the  
5 carboxylic acid chloride  $\{R^1-(CO)-Cl\}$  (1.5 eq.). After shaking the suspension for 2 h, an aliquot of water is added in order to hydrolyze the excess of the carboxylic acid chloride and shaking is continued for 1 h. The resin is then removed by filtration, washed with ethyl acetate and the solution is evaporated to yield the pure amide **3**.

10

The carboxylic acid chlorides  $\{R_1-(CO)-Cl\}$  may be obtained *in situ* from the corresponding carboxylic acid as described in the literature (i. e.: Devos, A.; Rémion, J.; Frisque-Hesbain, A.-M.; Colens, A.; Ghosez, L., *J. Chem. Soc., Chem. Commun.* **1979**, 1180).

15


The synthesis of the sulfonamide derivatives **5** from the amine **2** is performed in analogy to the above described procedure.

The urea derivatives **4** are obtained by reaction of the amines **2** in  
20 dichloromethane, with one equivalent isocyanate.

Typical procedure for the second reductive amination (Synthesis of compound **6**):

25 The amine (**2**) and the aldehyde or the ketone  $\{R_1R_2CO\}$  (1.5 eq.) are mixed in anhydrous dichloromethane and sodium triacetoxyborohydride (1.3 eq.) is added. After stirring the solution for 48h, methanol is added and the reaction mixture is treated in the same manner as described for amines **2**.

Scheme 2: Preparation of substituted 4-amino-N-(lower alkyl-aryl)-piperidines:




The N-Boc protected 4-amino-piperidine **7** (Scheme 2) can be prepared in a two step procedure starting by reacting 4-hydroxy-N-Boc-piperidine with methanesulfonylchloride in an inert solvent like DCM in the presence of a base like TEA to generate 4-mesyloxy-N-Boc-piperidine. The mesyloxy group is substituted with sodium azide followed by reduction of the azide functionality to the amino group to give **7**. The amine **7** is transformed to the secondary amine **8** via the typical procedure for the reductive amination described above. The synthesis of compounds **9**, **10**, **11** and **12** can also be performed via the typical procedures described above. Boc-deprotection is achieved either with hydrochloric acid in a solvent like diethylether or dioxane or with TFA in DCM. The second reductive amination step of the derivatives **13**, **14**, **15** and **16** to the fully derivatized final compounds **17**, **18**, **19** and **20** can be performed according to the typical procedure described above. Compounds **13**, **14**, **15** and **16** could also be transformed with acylating reagents like isocyanates, acid chlorides or sulfonyl chlorides to yield products with an urea-, amide- or sulfonamide functionality instead of the amine functionality at the ring nitrogen atom.

Compounds based on the 3-amino-piperidine template (see Scheme 3) can be prepared by using 3-amino-N-Boc-piperidine as starting material, which can be prepared as described for **7**. All other chemical transformations can be performed as described above in Scheme 2.


Compounds based on a 5- or 7-membered ring template (see Scheme 4) can be prepared according to the procedures described above.

The 7-membered ring **35** can be prepared by ring extension of 1-benzyl-4-piperidone with ethyl diazoacetate in presence of boron trifluoride etherate. Subsequent hydrolysis followed by decarboxylation upon heating a solution in 10% HCl gives the template **35**. Amine **36** is then obtained following the typical procedure for the second reductive amination.


Scheme 3:



Scheme 4:



Scheme 5: Synthesis of "Hydroxymethyl-Analogues":



- 5 According to the synthesis of the example shown in Scheme 5, other derivatives can be prepared by variation of the starting materials.

All chemical transformations can be performed according to well known standard methodologies as described in the literature or as described in the typical  
10 procedures above.



**The following examples illustrate the invention but do not limit the scope thereof.** All temperatures are stated in °C.

List of abbreviations:

5

Boc or boc    tert.-butoxycarbonyl

Cbz            benzyloxycarbonyl

DBU           1,8-diazabicyclo[5.4.0]undec-7-ene(1,5-5)

DCM           dichloromethane

10

DMF           dimethylformamide

DMSO          dimethylsulfoxide

EtOAc          ethyl acetate

TEA           triethylamine

TFA           trifluoroacetic acid

15

THF           tetrahydrofuran

TLC           thin layer chromatography

## General Procedures and Examples:

The following compounds were prepared according to the procedures described for the synthesis of compounds encompassed by the general formulae hereinbefore. All compounds were characterized by  $^1\text{H}$ -NMR (300MHz) and occasionally by  $^{13}\text{C}$ -NMR (75MHz) (Varian Oxford, 300MHz; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet; m = multiplet), by LC-MS (Waters Micromass; ZMD-platform with ESI-probe with Alliance 2790 HT; Column: 2x30mm, Gromsil ODS4, 3 $\mu\text{m}$ , 120A; Gradient: 0 – 100% acetonitrile in water, 6 min, with 0.05% formic acid, flow: 0.45ml/min;  $t_r$  is given in minutes, or Finnigan AQA/HP 1100; Column: Develosil C30 Aqua, 50x4.6mm, 5 $\mu\text{m}$ ; Gradient: 5-95% acetonitrile in water, 1 min, with 0.03% TFA, flow:4.5 ml/min.), by TLC (TLC-plates from Merck, Silica gel 60 F<sub>254</sub>) and occasionally by melting point.

### a) General Procedures:

#### *Typical procedure A) for the reductive amination:*

The amine and the aldehyde (1.5 eq.) (which are used as starting materials, are known compounds or the synthesis is described above or below, respectively), are mixed in anhydrous methanol and stirred for 6 h. The mixture is then treated with sodium borohydride (1.5 eq.) and stirred for 2 h. Purified Amberlyst 15 or another suitable scavenger is added and the suspension is shaken for 12 h. The resin is then separated by filtration and washed with methanol. The secondary amine is removed from the resin by adding a 2 M methanolic ammonia solution. The resin is drained after 30 min and washed with methanol. The filtrate is evaporated to yield the pure secondary amine.

*Typical procedure B) for the acylation:*

To a solution of the amine in anhydrous ethyl acetate is added vacuum dried Amberlyst 21 or another suitable scavenger followed by the addition of the  
5 carboxylic acid chloride (1.5 eq.). After shaking the suspension for two hours, an aliquot of water is added in order to hydrolyze the excess of the carboxylic acid chloride and shaking is continued for 1 h. The resin is then removed by filtration, washed with ethyl acetate and the solution is evaporated to yield the pure amide.

10 *Typical procedure C) for the second reductive amination:*


The amine and the aldehyde (1.5 eq.) are mixed in anhydrous dichloromethane and sodium triacetoxyborohydride (1.3 eq.) is added. After stirring the solution for 48 h, methanol is added and the reaction mixture is treated in the same manner  
15 as described in procedure A).

*Typical procedure D) for the Suzuki coupling:*

To a solution of bromide in toluene is added the boronic acid (1.1 eq.) in  
20 isopropanol and a 2M aqueous solution of potassium carbonate (5 eq.). The mixture is purged with nitrogen for 10 min and tetrakis (triphenylphosphine) palladium (0.03 eq.) is added. After heating under reflux for 6 h, water is added to the cooled reaction mixture and the product is extracted with ethyl acetate. The organic phase is washed with brine and dried over sodium sulfate. The  
25 solvent is evaporated to give the crude aldehyde, which is purified by flash chromatography (ethyl acetate/heptane gradient).

**b) Examples:****Example 1:**

- 5 According to typical procedure B), the secondary amine **a)**, obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(4-Benzyloxybenzyl)-*N*-(1-benzylpiperidin-4-yl)-4-pentylbenzamide  
LC-MS:  $t_R$  = 4.95; ES+: 561.7

**Example 2:**

10

- According to typical procedure B), the secondary amine **b)**, obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-4-pentyl-*N*-(3-phenylpropyl) benzamide  
LC-MS:  $t_R$  = 4.82; ES+: 483.5

## Example 3:

According to typical procedure B), the secondary amine **c)**, obtained via typical procedure A), is reacted with 4-butoxybenzoyl chloride to give


5



*N*-(4-Benzyloxybenzyl)-*N*-(1-benzylpiperidin-4-yl)-4-butoxybenzamide  
LC-MS:  $t_R = 4.57$ ; ES+:563.44

## Example 4:

- 10 According to typical procedure B), the secondary amine **c)**, obtained via typical procedure A), is reacted with 4-ethylbenzoyl chloride to give




*N*-(4-Benzyloxybenzyl)-*N*-(1-benzylpiperidin-4-yl)-4-ethylbenzamide  
LC-MS:  $t_R = 4.32$ ; ES+:519.41

## Example 5:

According to typical procedure B), the secondary amine **c)**, obtained via typical procedure A), is reacted with heptanoyl chloride to give


5



Heptanoic acid (4-benzyloxybenzyl)-(1-benzylpiperidin-4-yl) amide  
LC-MS:  $t_R$  = 4.42; ES<sup>+</sup>: 499.39

## Example 6:

- 10 According to typical procedure B), the secondary amine **c)**, obtained via typical procedure A), is reacted with dodecanoyl chloride to give




Dodecanoic acid (4-benzyloxybenzyl)-(1-benzylpiperidin-4-yl) amide  
LC-MS:  $t_R$  = 5.22; ES<sup>+</sup>: 569.56

## Example 7:

According to typical procedure B), the secondary amine **d)**, obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give


5



*N*-(1-Benzylpiperidin-4-yl)-4-pentyl-*N*-(4-phenoxybenzyl) benzamide  
LC-MS:  $t_R$  = 4.80; ES+: 547.46

## Example 8:

- 10 According to typical procedure B), the secondary amine **d)**, obtained via typical procedure A), is reacted with 4-butoxybenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-4-butoxy-*N*-(4-phenoxybenzyl) benzamide  
LC-MS:  $t_R$  = 4.60; ES+: 549.47

## Example 9:

According to typical procedure B), the secondary amine **d)**, obtained via typical procedure A), is reacted with dodecanoyl chloride to give


5



Dodecanoic acid (1-benzylpiperidin-4-yl)-(4-phenoxybenzyl) amide  
LC-MS:  $t_R$  = 5.16; ES<sup>+</sup>: 555.50

## Example 10:

10 According to typical procedure B), the secondary amine **e)**, obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-*N*-(3,4-bis-benzyloxybenzyl)-4-pentylbenzamide  
LC-MS:  $t_R$  = 5.05; ES<sup>+</sup>: 667.55



## Example 11:

According to typical procedure B), the secondary amine **e)**, obtained via typical procedure A), is reacted with 4-butoxybenzoyl chloride to give


5



*N*-(1-Benzylpiperidin-4-yl)-*N*-(3,4-bis-benzyloxybenzyl)-4-butoxybenzamide  
LC-MS:  $t_R$  = 4.83; ES+: 669.49

## Example 12:

10 According to typical procedure B), the secondary amine **e)**, obtained via typical procedure A), is reacted with 4-ethylbenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-*N*-(3,4-bis-benzyloxybenzyl)-4-ethylbenzamide  
LC-MS:  $t_R$  = 4.59; ES+: 625.61

## Example 13:

According to typical procedure B), the secondary amine **e**), obtained via typical procedure A), is reacted with dodecanoyl chloride to give


5



Dodecanoic acid (1-benzylpiperidin-4-yl)-(3,4-bis-benzyloxybenzyl) amide  
LC-MS:  $t_R$  = 5.49; ES+: 675.74

## Example 14:

- 10 According to typical procedure B), the secondary amine **f**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-*N*-biphenyl-4-ylmethyl-4-pentylbenzamide  
LC-MS:  $t_R$  = 4.82; ES+: 531.46

## Example 15:

According to typical procedure B), the secondary amine **f)**, obtained via typical procedure A), is reacted with 4-butoxybenzoyl chloride to give

5




*N*-(1-Benzylpiperidin-4-yl)-*N*-biphenyl-4-ylmethyl-4-butoxybenzamide  
LC-MS:  $t_R$  = 4.49; ES+: 533.43

## Example 16:

10

According to typical procedure B), the secondary amine **f)**, obtained via typical procedure A), is reacted with dodecanoyl chloride to give




Dodecanoic acid (1-benzylpiperidin-4-yl)-biphenyl-4-ylmethylamide  
LC-MS:  $t_R$  = 5.22; ES+: 539.51

## Example 17:

According to typical procedure B), the secondary amine **g**), obtained via typical procedure A), is reacted with 4-*tert*-butylbenzoyl chloride to give


5



*N*-(1-Benzylpiperidin-4-yl)-4-*tert*-butyl-*N*-(2-pentyl-3-phenylallyl) benzamide  
LC-MS:  $t_R$  = 4.93; ES+: 537.48

## Example 18:

- 10 According to typical procedure B), the secondary amine **h**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-4-pentyl-*N*-(4-trifluoromethylbenzyl) benzamide  
LC-MS:  $t_R$  = 4.58; ES+: 523.43

## Example 19:

According to typical procedure B), the secondary amine **h)**, obtained via typical procedure A), is reacted with 4-butoxybenzoyl chloride to give

5




*N*-(1-Benzylpiperidin-4-yl)-4-butoxy-*N*-(4-trifluoromethylbenzyl) benzamide  
LC-MS:  $t_R = 4.34$ ; ES<sup>+</sup>: 525.48

## Example 20:

10

According to typical procedure B), the secondary amine **h)**, obtained via typical procedure A), is reacted with dodecanoyl chloride to give




Dodecanoic acid (1-benzylpiperidin-4-yl)-(4-trifluoromethylbenzyl) amide  
LC-MS:  $t_R = 5.03$ ; ES<sup>+</sup>: 531.43

15

## Example 21

According to typical procedure B), the secondary amine **i**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give

5




*N*-(3-Benzyloxy-4-methoxybenzyl)-*N*-(1-benzylpiperidin-4-yl)-  
4-pentylbenzamide

LC-MS:  $t_R$  = 4.62; ES<sup>+</sup>: 591.43

## Example 22:

10 According to typical procedure B), the secondary amine **j**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(4-Benzyloxy-3-methoxybenzyl)-*N*-(1-benzylpiperidin-4-yl)-  
4-pentylbenzamide

LC-MS:  $t_R$  = 4.70; ES<sup>+</sup>: 591.46

## Example 23:

According to typical procedure B), the secondary amine **j**), obtained via typical procedure A), is reacted with dodecanoyl chloride to give

5




Dodecanoic acid (4-benzyloxy-3-methoxybenzyl)-(1-benzylpiperidin-4-yl)  
amide

LC-MS:  $t_R$  = 5.12; ES<sup>+</sup>: 599.71

## Example 24:

According to typical procedure B), the secondary amine **k**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give

10




*N*-(1-Benzylpiperidin-4-yl)-*N*-(4-butylbenzyl)-4-pentylbenzamide

LC-MS:  $t_R$  = 5.02; ES<sup>+</sup>: 511.56

## Example 25:

According to typical procedure B), the secondary amine **l**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give


5



*N*-(1-Benzylpiperidin-4-yl)-*N*-(4-butoxybenzyl)-4-pentylbenzamide  
LC-MS:  $t_R$  = 4.92; ES+: 527.58

## Example 26:

- 10 According to typical procedure B), the secondary amine **m**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give




*N*-(1-Benzylpiperidin-4-yl)-4-pentyl-*N*-(4-pentylbenzyl) benzamide  
LC-MS:  $t_R$  = 5.14; ES+: 525.60



## Example 27:

According to typical procedure B), the secondary amine **a)**, obtained via typical procedure A), is reacted with 4-butylphenylisocyanate to give


5



1-(4-Benzyloxybenzyl)-1-(1-benzylpiperidin-4-yl)-3-(4-butylphenyl) urea  
LC-MS:  $t_R$  = 4.70; ES<sup>+</sup>: 562.53

## Example 28:

- 10 According to typical procedure B), the secondary amine **n)**, which is prepared as indicated in scheme 4, is reacted with 4-pentylbenzoyl chloride to give




*N*-[(1*S*)-1-(4-Benzyloxyphenyl)-2-hydroxyethyl]-*N*-(1-benzylpiperidin-4-yl)-4-pentylbenzamide  
LC-MS:  $t_R$  = 4.47; ES<sup>+</sup>: 591.61

## Example 29:

According to typical procedure B), the secondary amine **a)**, obtained via typical procedure A), is reacted with 4-propylphenylsulfonyl chloride to give

5




*N*-(4-Benzyloxybenzyl)-*N*-(1-benzylpiperidin-4-yl)-4-propyl  
benzenesulfonamide

LC-MS:  $t_R$  = 4.63; ES+: 569.56

## Example 30:

10 According to typical procedure C), the secondary amine **m)**, obtained via typical procedure A), is reacted with 4-trifluoromethylbenzaldehyde to give




(1-Benzylpiperidin-4-yl)-(4-pentylbenzyl)-(4-trifluoromethylbenzyl) amine

LC-MS:  $t_R$  = 4.91; ES+: 509.60

## Example 31:

According to typical procedure C), the secondary amine **m**), obtained via typical procedure A), is reacted with biphenyl-4-carbaldehyde to give


5.



(1-Benzylpiperidin-4-yl)-biphenyl-4-ylmethyl-(4-pentylbenzyl) amine  
LC-MS:  $t_R = 4.84$ ; ES+: 517.55

## Example 32:

- 10 According to typical procedure C), the secondary amine **o**), obtained via typical procedures A) and B), is reacted with furan-3-carbaldehyde to give




*N*-(4'-Cyanobiphenyl-4-ylmethyl)-*N*-(1-furan-3-ylmethylpiperidin-4-yl)-4-pentylbenzamide  
LC-MS:  $t_R = 1.05$  ; ES+: 546.19

## Example 33:

According to typical procedure C), the secondary amine **p**), obtained via typical procedure A), is reacted with 4-pentylbenzaldehyde to give

5




2-(4'-{[(1-Benzylpiperidin-4-yl)-(4-pentylbenzyl)-amino]methyl}biphenyl-4-yloxy)ethanol  
LC-MS:  $t_R = 4.32$  ; ES+:577.49

## Example 34:

According to typical procedure C), the secondary amine **q**), which is prepared as indicated in Scheme 4, is reacted with 4-pentylbenzaldehyde to give


10



(rac.)-(1-Benzylazepan-4-yl)biphenyl-4-ylmethyl-(4-pentylbenzyl) amine  
LC-MS:  $t_R = 4.41$  ; ES+:531.53

## Example 35:

According to typical procedure B), the secondary amine **q**), which is prepared as indicated in Scheme 4, is reacted with 4-pentylbenzoyl chloride to give




(*rac.*)-N-(1-Benzylazepan-4-yl)-N-biphenyl-4-ylmethyl-4-pentyl benzamide  
LC-MS:  $t_R = 4.94$ ; ES+:545.42

5

## Example 36:

According to typical procedure B), the secondary amine **r**), obtained via typical procedure A), is reacted with 4-pentylbenzoyl chloride to give


10



N-((3S)-1-Benzylpyrrolidin-3-yl)-N-biphenyl-4-ylmethyl-4-pentylbenzamide  
LC-MS:  $t_R = 5.08$  ; ES+:517.44

## Example 37:

According to typical procedure B), the secondary amine **s**), obtained via typical procedure C), is reacted with 4-pentylbenzoyl chloride to give



*N*-(4-Benzyloxyphenyl)-*N*-(1-benzylpiperidin-4-yl)-4-pentylbenzamide

LC-MS:  $t_R = 4.57$  ; ES+: 547.34

5

## Additional Examples:

Example Nr	Compound	LC-MS	Synthesis according to example	IC <sub>50</sub> (nM) on plasmepsin II
38	N-(1-Cyclohex-1-enylmethyl-piperidin-4-yl)-N-(3',4'-dimethoxybiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=0.82^a$ ES+: 595.26	32	19
39	N-[1-(3-Methylbutyl) piperidin-4-yl]-4-pentyl-N-(4-pyridin-3-yl-benzyl) benzamide	$t_R=3.78$ ES+: 512.56	32	20
40	N-(4'-Cyanobiphenyl-4-ylmethyl)-N-(1-cyclohex-1-enylmethyl-piperidin-4-yl)-4-pentylbenzamide	$t_R=1.09^a$ ES+: 560.25	32	25
41	N-(3',4'-Dimethoxybiphenyl-4-ylmethyl)-4-pentyl-N-(1-pyridin-4-ylmethylpiperidin-4-yl) benzamide	$t_R=0.95^a$ ES+: 592.24	32	25

42	N-(4'-Cyano-biphenyl-4-ylmethyl)-4-pentyl-N-(1-pyridin-4-ylmethyl-piperidin-4-yl) benzamide	$t_R=0.71^a$ ES+: 557.20	32	28
43	N-(3',4'-Dimethoxybiphenyl-4-ylmethyl)-N-(1-furan-3-ylmethyl-piperidin-4-yl)-4-pentylbenzamide	$t_R=0.79^a$ ES+: 581.21	32	31
44	N-[4'-(2-Hydroxyethoxy)-biphenyl-4-ylmethyl]-4-pentyl-N-(1-pyridin-4-ylmethylpiperidin-4-yl) benzamide	$t_R=0.89^a$ ES+: 592.24	32	39
45	4-Pentyl-N-(4-pyridin-3-yl-benzyl)-N-(1-thiophen-3-ylmethyl-piperidin-4-yl) benzamide	$t_R=3.73$ ES+: 538.33	32	42
46	N-(3',4'-Dimethoxybiphenyl-4-ylmethyl)-4-pentyl-N-(1-pyridin-3-ylmethylpiperidin-4-yl) benzamide	$t_R=0.96^a$ ES+: 592.26	32	45
47	N-(1-Cyclohexylmethyl-piperidin-4-yl)-4-pentyl-N-(4-pyridin-3-yl-benzyl) benzamide	$t_R=3.90$ ES+: 538.38	32	46
48	N-(1-Benzylpiperidin-4-yl)-N-(3',4'-dimethoxybiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=4.58$ ES+: 591.57	14	48
49	N-(4-Benzo[1,3]dioxol-5-yl-benzyl)-N-(1-furan-3-ylmethyl-piperidin-4-yl)-4-pentylbenzamide	$t_R=4.72$ ES+: 565.37	32	52
50	N-(4-Benzo[1,3]dioxol-5-yl-benzyl)-4-pentyl-N-(1-pyridin-4-ylmethylpiperidin-4-yl) benzamide	$t_R=4.59$ ES+: 576.60	32	54
51	N-(1-Furan-3-ylmethylpiperidin-4-yl)-N-[4'-(2-hydroxyethoxy) biphenyl-4-ylmethyl]-4-pentylbenzamide	$t_R=0.98^a$ ES+: 581.22	32	57

52	N-(4-Benzo[1,3]dioxol-5-yl-benzyl)-N-(1-benzylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.87$ ES+: 575.61	14	58
53	N-(1-Benzylpiperidin-4-yl)-N-(2'-fluorobiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=4.65$ ES+: 549.47	14	61
54	N-(1-Furan-3-ylmethylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-3-yl-benzyl) benzamide	$t_R=3.96$ ES+: 522.42	32	64
55	N-(4'-Cyanobiphenyl-4-ylmethyl)-4-pentyl-N-(1-pyridin-3-ylmethyl-piperidin-4-yl) benzamide	$t_R=0.72^a$ ES+: 557.18	32	68
56	N-Biphenyl-4-ylmethyl-N-[1-(4-methoxybenzyl) piperidin-4-yl]-4-pentylbenzamide	$t_R=5.02$ ES+: 561.57	32	71
57	N-(4-Benzo[1,3]dioxol-5-yl-benzyl)-N-(1-cyclohex-1-enylmethyl-piperidin-4-yl)-4-pentyl-benzamide	$t_R=5.20$ ES+: 579.55	32	75
58	N-(1-Benzyl-piperidin-4-yl)-N-[4-(4-fluoro-benzyloxy)-benzyl]-4-pentyl-benzamide	$t_R=4.83$ ES+: 579.71	1	79
59	N-(1-Benzyl-piperidin-4-yl)-N-(4'-cyano-biphenyl-4-ylmethyl)-4-pentyl-benzamide	$t_R=4.69$ ES+: 556.58	14	81
60	N-(2'-Fluorobiphenyl-4-ylmethyl)-N-(1-furan-3-ylmethylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.77$ ES+: 539.36	32	87
61	N-(1-Cyclohex-1-enylmethyl-piperidin-4-yl)-4-pentyl-N-(4-pyridin-3-yl-benzyl) benzamide	$t_R=4.44$ ES+: 536.44	32	89



62	N-(4-Benzo[1,3]dioxol-5-yl-benzyl)-N-[1-(4-hydroxybenzyl)piperidin-4-yl]-4-pentylbenzamide	$t_R=4.89$ ES+: 591.72	32	90
63	N-(2'-Fluorobiphenyl-4-ylmethyl)-4-pentyl-N-(1-pyridin-4-ylmethylpiperidin-4-yl) benzamide	$t_R=4.65$ ES+: 550.40	32	95
64	4-Pentyl-N-(4-pyridin-3-yl-benzyl)-N-(1-pyridin-4-ylmethylpiperidin-4-yl) benzamide	$t_R=3.72$ ES+: 533.24	32	102
65	N-Biphenyl-4-ylmethyl-4-pentyl-N-(1-pyridin-3-ylmethylpiperidin-4-yl) benzamide	$t_R=4.54$ ES+: 532.46	32	103
66	N-(1-Benzylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-4-ylbenzyl) benzamide	$t_R=4.22$ ES+: 532.48	14	104
67	N-[1-(4-Hydroxybenzyl) piperidin-4-yl]-4-pentyl-N-(4-pyridin-3-yl-benzyl) benzamide	$t_R=4.00$ ES+: 548.42	32	105
68	N-(1-Benzylpiperidin-4-yl)-N-(2'-chlorobiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=4.76$ ES+: 565.60	14	120
69	N-(1-Cyclohex-1-enylmethylpiperidin-4-yl)-N-(2'-fluorobiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=5.30$ ES+: 553.49	32	123
70	N-(1-Cyclohex-1-enylmethylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-2-ylbenzyl) benzamide	$t_R=4.64$ ES+: 536.49	32	125
71	N-Biphenyl-4-ylmethyl-N-(1-furan-3-ylmethylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.68$ ES+: 521.40	32	127

72	N-[1-(5-Hydroxymethyl-furan-2-ylmethyl) piperidin-4-yl]-4-pentyl-N-(4-pyridin-3-ylbenzyl) benzamide	$t_R=3.52$ ES+: 552.20	32	128
73	N-(1-Cyclopropylmethylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-3-ylbenzyl) benzamide	$t_R=3.65$ ES+: 496.36	32	128
74	N-(1-Benzylpiperidin-4-yl)-N-(3'-methylbiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=4.97$ ES+: 545.42	14	140
75	N-(4-Benzoyloxybenzyl)-N-((3S)-1-benzylpyrrolidin-3-yl)-4-pentylbenzamide	$t_R=5.00$ ES+: 547.37	36	141
76	N-(2'-Fluorobiphenyl-4-ylmethyl)-N-[1-(4-hydroxybenzyl) piperidin-4-yl]-4-pentylbenzamide	$t_R=4.95$ ES+: 565.56	32	152
77	N-(1-Benzylpiperidin-4-yl)-N-(3-fluoro-4-trifluoromethylbenzyl)-4-pentylbenzamide	$t_R=4.58$ ES+: 541.30	1	153
78	N-(1-Furan-3-ylmethylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-2-ylbenzyl) benzamide	$t_R=4.24$ ES+: 522.33	32	168
79	4-Pentyl-N-(4-pyridin-2-yl-benzyl)-N-(1-pyridin-4-ylmethylpiperidin-4-yl) benzamide	$t_R=3.97$ ES+: 533.49	32	176
80	N-(1-Benzylpiperidin-4-yl)-4-pentyl-N-(4-trifluoromethoxybenzyl) benzamide	$t_R=4.61$ ES+: 539.46	1	187
81	N-Biphenyl-4-ylmethyl-N-[1-(4-hydroxybenzyl) piperidin-4-yl]-4-pentylbenzamide	$t_R=4.68$ ES+: 547.43	32	192









82	N-Biphenyl-4-ylmethyl-N-(1-cyclohex-1-enylmethylpiperidin-4-yl)-4-pentylbenzamide	$t_R=5.11$ ES+: 535.47	32	196
83	N-(1-Benzylpiperidin-4-yl)-N-(4-isopropoxybenzyl)-4-pentylbenzamide	$t_R=4.60$ ES+: 513.35	1	204
84	N-(1-Benzylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-2-yl-benzyl) benzamide	$t_R=4.25$ ES+: 518.45	14	209
85	N-(1-Benzofuran-2-ylmethylpiperidin-4-yl)-4-pentyl-N-(4-pyridin-3-yl-benzyl) benzamide	$t_R=3.99$ ES+: 572.35	32	211
86	N-(1-Benzylpiperidin-4-yl)-N-naphthalen-2-ylmethyl-4-pentylbenzamide	$t_R=4.50$ ES+: 505.17	1	248
87	N-(1-Benzylpiperidin-4-yl)-4-pentyl-N-(4-pyrimidin-5-ylbenzyl) benzamide	$t_R=4.15$ ES+: 533.40	14	250
88	(1-Benzylpiperidin-4-yl)-(3',4'-dimethoxybiphenyl-4-ylmethyl)-(4-pentyl-benzyl) amine	$t_R=4.74$ ES+: 577.40	33	255
89	N-(1-Benzylpiperidin-4-yl)-N-(4'-fluorobiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=4.77$ ES+: 549.43	14	260
90	N-(4-Allyloxybenzyl)-N-(1-benzylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.56$ ES+: 511.57	1	270
91	(4-Benzo[1,3]dioxol-5-yl-benzyl)-(1-benzylpiperidin-4-yl)-(4-pentyl-benzyl) amine	$t_R=4.68$ ES+: 561.53	33	275


92	N-(4-Benzyloxy-2-hydroxy-benzyl)-N-(1-benzylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.76$ ES+: 577.60	1	281
93	N-Benzo[1,3]dioxol-5-ylmethyl-N-(1-benzylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.50$ ES+: 499.37	1	284
94	N-(1-Benzylpiperidin-4-yl)-N-(4-ethoxybenzyl)-4-pentylbenzamide	$t_R=4.64$ ES+: 499.42	1	284
95	4'-{[(1-Benzylpiperidin-4-yl)-(4-pentylbenzyl) amino] methyl}-biphenyl-4-carbonitrile	$t_R=4.90$ ES+: 542.33	14	294
96	N-Biphenyl-4-ylmethyl-4-pentyl-N-[1-(3-trifluoromethylbenzyl) piperidin-4-yl] benzamide	$t_R=5.17$ ES+: 599.67	32	319
97	N-(1-Benzylpiperidin-4-yl)-N-biphenyl-4-ylmethyl-4-hexylbenzamide	$t_R=4.82$ ES+: 545.49	14	322
98	N-(1-Benzylpiperidin-4-yl)-N-(4-methoxybenzyl)-4-pentylbenzamide	$t_R=4.30$ ES+: 485.34	1	322
99	N-Biphenyl-4-ylmethyl-N-[1-(2-hydroxybenzyl) piperidin-4-yl]-4-pentylbenzamide	$t_R=4.80$ ES+: 547.50	32	361
100	<i>trans</i> -4-Pentylcyclohexane carboxylic acid (1-benzylpiperidin-4-yl)-biphenyl-4-ylmethyl amide	$t_R=4.91$ ES+: 537.34	14	374
101	N-Biphenyl-4-ylmethyl-N-[1-(4-fluorobenzyl) piperidin-4-yl]-4-pentylbenzamide	$t_R=4.98$ ES+: 549.48	32	385

102	(1-Benzylpiperidin-4-yl)-[4-(4-fluorobenzyloxy) benzyl]-(4-pentylbenzyl) amine	$t_R=4.71$ ES+: 565.63	33	414
103	(4-Benzyloxybenzyl)-(1-benzylpiperidin-4-yl)-(4-pentylbenzyl) amine	$t_R=4.65$ ES+: 547.56	33	431
104	N-Biphenyl-4-ylmethyl-4-pentyl-N-(1-phenethylpiperidin-4-yl) benzamide	$t_R=4.91$ ES+: 545.47	32	433
105	( <i>rac.</i> )-N-(4-Benzyloxybenzyl)-N-(1-benzylpiperidin-3-yl)-4-pentylbenzamide	$t_R=4.97$ ES+: 561.46	1	458
106	N-(1-Benzylpiperidin-4-yl)-N-(4'-dimethylaminobiphenyl-4-ylmethyl)-4-pentylbenzamide	$t_R=4.65$ ES+: 574.54	14	461
107	(1-Benzylpiperidin-4-yl)-(4-pentylbenzyl)-(4-pyrimidin-5-ylbenzyl) amine	$t_R=4.36$ ES+: 519.38	14	618
108	(1-Benzylpiperidin-4-yl)-(4-pentylbenzyl)-(3'-trifluoromethylbiphenyl-4-ylmethyl) amine	$t_R=5.83$ ES+: 585.43	14	634
109	(1-Benzylpiperidin-4-yl)-(2'-fluorobiphenyl-4-ylmethyl)-(4-pentylbenzyl) amine	$t_R=4.96$ ES+: 535.41	14	656
110	N-Biphenyl-4-ylmethyl-4-pentyl-N-[1-(4-trifluoromethoxybenzyl) piperidin-4-yl] benzamide	$t_R=5.19$ ES+: 615.63	32	692
111	N-[(1 <i>S</i> )-2-(4-Benzyloxyphenyl)-1-hydroxymethylethyl]-N-(1-benzylpiperidin-4-yl)-4-pentylbenzamide	$t_R=4.32$ ES+: 605.52	28	749


112	N-(4-Benzyloxybenzyl)-4-pentyl-N-(1-phenethylpiperidin-4-yl) benzamide	$t_R=4.99$ ES+: 575.49	32	761
113	N-(1-Benzylpiperidin-4-yl)-4-pentyl-N-(3'-trifluoromethoxy-biphenyl-4-ylmethyl) benzamide	$t_R=5.11$ ES+: 615.52	14	816
114	N-(4-Benzyloxybenzyl)-N-((3R)-1-benzylpyrrolidin-3-yl)-4-pentyl-benzamide	$t_R=4.96$ ES+: 547.42	36	817
115	N-(1-Benzylpiperidin-4-yl)-N-(4-dibutylaminobenzyl)-4-pentyl-benzamide	$t_R=4.92$ ES+: 582.74	1	839
116	N-(1-Benzylpiperidin-4-yl)-N-(4-hydroxybenzyl)-4-pentyl-benzamide	$t_R=4.32$ ES+: 471.42	1	882
117	N-(1-Benzylpiperidin-4-yl)-4-pentyl-N-(2-pentyl-3-phenylallyl) benzamide	$t_R=5.21$ ES+: 551.62	1	933
118	4-Pentylbicyclo[2.2.2]octane-1-carboxylic acid (1-benzylpiperidin-4-yl)-biphenyl-4-ylmethanamide	$t_R=5.13$ ES+: 563.67	1	942

<sup>a</sup>LC-MS measured on the Finnigan AQA/HP system.


**Further Examples:****Example 119****Example 120****Example 121****Example 122****Example 123****Example 124****Example 125****Example 126**

**Example 127**


IC50: 77 nM

**Example 128**


IC50: 113 nM

**Example 129**


IC50: 41 nM

**Example 130**


IC50: 38 nM

**Example 131**


IC50: 154 nM

**Example 132**

IC50: 23 nM







**Example 133**

IC50: 41 nM

**Example 134**

IC50: 94 nM




**Example 135****Example 136****Example 137****Example 138****Example 139****Example 140**

**c) Referential Examples: (e.g. not commercially available starting materials)**

Referential Example 1:

5

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 2-(4-bromophenoxy) ethanol to give




4'-(2-Hydroxy-ethoxy)-biphenyl-4-carbaldehyde

10

Referential Example 2:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 1-bromo-2-fluorobenzene to give

15




2'-Fluoro-biphenyl-4-carbaldehyde

## Referential Example 3:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 1-bromo-3-trifluoromethylbenzene to give


5



3'-Trifluoromethylbiphenyl-4-carbaldehyde

## Referential Example 4:


- 10 According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 1-bromo-2-chlorobenzene to give



2'-Chlorobiphenyl-4-carbaldehyde

- 15 Referential Example 5:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 5-bromopyrimidine to give




4-Pyrimidin-5-yl-benzaldehyde

20

## Referential Example 6:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 1-bromo-3-(trifluoromethoxy)benzene to give


5



3'-Trifluoromethoxybiphenyl-4-carbaldehyde

## Referential Example 7:


10 According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 1-bromo-3,4-dimethoxybenzene to give



3',4'-Dimethoxybiphenyl-4-carbaldehyde

## 15 Referential Example 8:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 5-bromo-benzo[1,3]dioxole to give




20

4-Benzo[1,3]dioxol-5-yl-benzaldehyde

## Referential Example 9:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 3-bromopyridine to give


5



4-Pyridin-3-yl-benzaldehyde

## Referential Example 10:


10 According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 4-bromopyridine to give



4-Pyridin-4-yl-benzaldehyde

## 15 Referential Example 11:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 4-bromobenzonitrile to give




4'-Formylbiphenyl-4-carbonitrile

20

## Referential Example 12:

According to typical procedure D), 4-formylbenzeneboronic acid is coupled with 3-bromotoluene to give






5




3'-Methylbiphenyl-4-carbaldehyde

## Referential Example 13:

- 10 The following biaryl-derivatives could be prepared according to the typical procedure D):



**Claims:**1. Compounds of the general **formula I****General Formula I**

wherein

**Q** represents  $-\text{SO}_2-\text{R}^1$ ;  $-\text{CO}-\text{R}^1$ ;  $-\text{CO}-\text{NH}-\text{R}^1$ ;  $-\text{CO}-\text{N}(\text{R}^1)(\text{R}^2)$ ;  $-\text{CO}-\text{OR}^1$ ;  
 $-(\text{CH}_2)_p-\text{R}^1$ ;  $-(\text{CH}_2)_p-\text{CH}(\text{R}^1)(\text{R}^2)$ ;

**X** represents  $-\text{SO}_2-\text{R}^1$ ;  $-\text{CO}-\text{R}^1$ ;  $-\text{CO}-\text{NH}-\text{R}^1$ ;  $-\text{CO}-\text{N}(\text{R}^1)(\text{R}^2)$ ;  $-\text{CO}-\text{OR}^1$ ;  
 $-(\text{CH}_2)_p-\text{R}^1$ ;  $-(\text{CH}_2)_p-\text{CH}(\text{R}^1)(\text{R}^2)$ ; hydrogen;

**R**<sup>1</sup>, **R**<sup>2</sup> and **R**<sup>3</sup> represent lower alkyl; lower alkenyl; aryl; heteroaryl; cycloalkyl;  
heterocyclyl; aryl-lower alkyl; heteroaryl-lower alkyl; cycloalkyl-lower alkyl;  
heterocyclyl-lower alkyl; aryl-lower alkenyl; heteroaryl-lower alkenyl; cycloalkyl-  
lower alkenyl; heterocyclyl-lower alkenyl;

**R**<sup>4</sup> represents hydrogen;  $-\text{CH}_2-\text{OR}^5$ ;  $-\text{CO}-\text{OR}^5$ ;

$R^5$  represents hydrogen, lower alkyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl-lower alkyl; aryl-lower alkyl; heteroaryl-lower alkyl; heterocyclyl-lower alkyl;

- 5  $t$  represents the whole numbers 0 (zero) or 1, in case  $t$  represents the whole number 0 (zero),  $R^4$  is absent;


$m$  represents the whole numbers 2, 3 or 4;

- 10  $n$  represents the whole numbers 1 or 2;

$p$  represents the whole numbers 0 (zero), 1 or 2;

- and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of  
15 diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof

## 2. Compounds of formula II



**Formula II**

20


wherein

X, Q,  $t$ ,  $R^3$  and  $R^4$  are as defined in general formula I above



and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof.


5    3. Compounds of **formula III**



wherein

10    **Q**, **t**, **R<sup>3</sup>** and **R<sup>4</sup>** are as defined in general formula I above

and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof.

4. Compounds of **formula IV****Formula IV**


5

wherein

**Q** is as defined in general formula I above

10

and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof.

5. Compounds of **formula V**

5 and pure enantiomers, mixtures of enantiomers, pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and pharmaceutically acceptable salts thereof.

6. A compound as described as end-product in any of the examples 1 to 140.

10

7. Pharmaceutical compositions containing one or more compounds as claimed in any one of claims 1 to 6 and inert excipients.

8. Pharmaceutical compositions according to claim 7 for treatment of diseases  
15 demanding the inhibition of aspartic proteases.

9. Pharmaceutical compositions according to claim 7 for treatment of disorders associated with the role of plasmeprin II and which require selective inhibition of plasmeprin II.

20

10. Pharmaceutical compositions according to claim 7 for treatment or prevention of malaria.

11. Pharmaceutical compositions according to claim 7 for treatment or prevention of diseases caused by protozoal infection (e.g. Chagas disease, Sleeping sickness etc).

5

12. Pharmaceutical compositions according to claim 7, which contain aside of one or more compounds of the general formula I a known plasmepsin II, a known HIV protease or a known cathepsin D or E inhibitor.

10 13. A process for the preparation of a pharmaceutical composition according to any one of claims 8 to 11, characterized by mixing one or more active ingredients according to any one of claims 1 to 6 with inert excipients in a manner known per se.

15 14. Use of at least one of the compounds of the general formula I for the treatment or prevention of diseases.

15. The invention as herein before described.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/10272

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/58 A61K31/435 A61P33/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 05336 A (LO CASTRO STEPHEN ;MARQUIS ROBERT W JR (US); SMITHKLINE BEECHAM CO) 12 February 1998 (1998-02-12) page 23, line 28; claim 1 ---	4-14
A	CARROLL C D ET AL: "Identification of potent inhibitors of plasmodium falciparum plasmepsin II from an encoded statine combinatorial library" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 17, 8 September 1998 (1998-09-08), pages 2315-2320, XP004138224 ISSN: 0960-894X the whole document --- -/--	4-14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

3 January 2002

Date of mailing of the international search report

16/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/10272

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 12532 A (HOFFMANN LA ROCHE ;MATILE HUGUES (CH); BUR DANIEL (CH); FISCHLI WA) 18 March 1999 (1999-03-18) page 19; claim 1 ---	4-14
X	N. J. HARPER; C. F. CHIGNELL: "The chemistry and pharmacology of some 4-aminopiperidines and their derivatives" J. MED. CHEM., vol. 7, 1964, pages 729-732, XP001037233 examples 21-23; table I ---	4,7
X	A. F. CASY; M. R. HUCKSTEP: "Structure-Activity Studies of Fentanyl" J. PHARM. PHARMACOL., vol. 40, 1988, pages 605-608, XP001037232 table 2 ---	4,7
E	WO 01 66521 A (ULDAM A K ;HANSEN E L (DK); ANDERSSON CARL M (DK); CROSTON GLENN ()) 13 September 2001 (2001-09-13) claim 6 ---	4-14
E	WO 01 81308 A (MADDAFORD SHAWN P ;SLASSI ABDELMALIK (CA); TSE HOI LUN ALLAN (CA);) 1 November 2001 (2001-11-01) * see p. 56 Exp. no. 1.9; p. 56 Exp. no. 1,3; p. 59, Exp. no. 1.29, p. 60 Exp. no. 1.26; p. 61 Exp. no. 1.14, 1.13, 1.12, 1.10, 1.27, 1.28 * -----	4-14

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Claims Nos.: 1-3

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to the compounds of formula (IV).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 1/EP 01/10272

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9805336	A	12-02-1998	AP 865 A	17-08-2000
			AU 711014 B2	07-10-1999
			AU 1270797 A	17-07-1997
			AU 721853 B2	13-07-2000
			AU 3972697 A	25-02-1998
			BG 101712 A	27-02-1998
			BG 103144 A	30-09-1999
			BR 9711044 A	24-10-2000
			CA 2209109 A1	09-05-1997
			CN 1177293 A	25-03-1998
			CN 1232399 A	20-10-1999
			CZ 9900362 A3	14-07-1999
			CZ 9702060 A3	17-02-1999
			EP 0804180 A1	05-11-1997
			EP 0936912 A1	25-08-1999
			HU 9802488 A2	01-02-1999
			HU 9902409 A2	29-11-1999
			JP 2000516920 T	19-12-2000
			JP 10512300 T	24-11-1998
			NO 973009 A	27-08-1997
			NO 990548 A	07-04-1999
			PL 328877 A1	01-03-1999
			PL 331533 A1	19-07-1999
			SK 16299 A3	10-12-1999
			SK 48198 A3	07-10-1998
			SK 88997 A3	06-05-1998
			TR 9700560 T1	21-11-1997
			TR 9900249 T2	21-04-1999
			WO 9716177 A1	09-05-1997
			WO 9805336 A1	12-02-1998
			US 6274336 B1	14-08-2001
			ZA 9707032 A	04-08-1998
WO 9912532	A	18-03-1999	AU 9740998 A	29-03-1999
			WO 9912532 A2	18-03-1999
WO 0166521	A	13-09-2001	WO 0166521 A1	13-09-2001
WO 0181308	A	01-11-2001	WO 0181308 A2	01-11-2001